newsfilter
← Latest News
ClinicalTrials.gov·

Phase 3 Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) - NCT04526665

Effect of elafibranor (80 mg/day) on cholestasis, Response to treatment based on ALP normalization, Change in pruritis from baseline